Avalo Therapeutics announced the payoff of the remainder of its $35 million debt owed to Horizon Technology Finance Corporation. This significant milestone not only signifies the company's steadfast commitment to financial stability but also paves the way for future accelerated growth and progress toward executing its ambitious plans to advance its most promising drug candidates, including its anti-LIGHT mAb (quisovalimab or AVTX-002) and its BTLA agonist fusion protein (AVTX-008).
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
10.85 USD | -5.57% | -24.44% | +19.23% |
Apr. 17 | North American Morning Briefing : Stock Futures -2- | DJ |
Apr. 16 | Oppenheimer Upgrades Avalo Therapeutics to Outperform From Perform, Price Target is $35 | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+19.23% | 11.22M | |
+17.96% | 44.96B | |
+48.77% | 41.85B | |
+1.17% | 42.65B | |
-4.27% | 29.04B | |
+11.42% | 26.08B | |
-21.39% | 19.03B | |
+4.86% | 12.75B | |
+27.29% | 12.06B | |
-3.50% | 11.75B |
- Stock Market
- Equities
- AVTX Stock
- News Avalo Therapeutics, Inc.
- Avalo Therapeutics Successfully Eliminates $35 Million Debt Paving the Way for Future Growth and Innovation